

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Neither this announcement nor any copy thereof may be released into or distributed, directly or indirectly, in the United States or any other jurisdiction where such release or distribution might be unlawful. This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase, or subscribe for any securities of the Company.

This announcement does not constitute or form a part of any offer to sell or solicitation to purchase or subscribe for securities in the United States or in any other jurisdictions where such offer is unlawful. The Company's shares mentioned in this announcement have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") and may not be offered or sold in the United States except pursuant to registration or an exemption from the registration requirements of the U.S. Securities Act. The Company has no intention to register under the U.S. Securities Act any of the securities referred to herein or to conduct a public offering of securities in the United States.



CANbridge Pharmaceuticals Inc.
北海康成製藥有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1228)

**COMPLETION OF SUBSCRIPTION OF
NEW SHARES UNDER GENERAL MANDATE**

COMPLETION OF THE SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE

Reference is made to the announcement of the Company dated February 16, 2026.

The Board is pleased to announce that the conditions set out in the Subscription Agreement had been fulfilled and Closing took place on March 10, 2026 in accordance with the terms and conditions of the Subscription Agreement. The Company allotted and issued a total of 84,033,613 Subscription Shares to the Subscriber at the Subscription Price of HK\$2.38 per Subscription Share on the Closing Date.

The table below sets out the changes to the shareholding structure of the Company upon Closing:

Shareholders	Immediately before the Closing		Immediately after the Closing	
	Number of Shares	% ⁽¹⁾	Number of Shares	% ⁽¹⁾
Dr. James Xue	26,042,380 ⁽²⁾	5.09	26,042,380 ⁽²⁾	4.37
	15,000,000 ⁽³⁾	2.93	15,000,000 ⁽³⁾	2.52
	839,141 ⁽⁴⁾	0.16	839,141 ⁽⁴⁾	0.14
Mr. James Arthur Geraghty	700,000	0.14	700,000	0.12
Baheal	97,149,468	19.00	97,149,468	16.32
The Subscriber	12,826,080	2.51	96,859,693	16.26
Other public Shareholders	358,852,665	70.17	358,852,665	60.27
Total number of Shares	<u>511,409,734</u>	<u>100.00</u>	<u>595,443,347</u>	<u>100.00</u>

Notes:

- (1) The aggregate of the percentage figures in the table above may not add up to the relevant sub-total or total percentage figures shown due to rounding of the percentage figures to two decimal places.
- (2) CTX Pharma Holdings Limited directly held 26,042,380 Shares and is wholly-owned by Dr. Xue.
- (3) 15,000,000 Shares are held by JQX 2021 Gift Trust (a trust set up by Dr. Xue as settlor, the spouse of Dr. Xue as trustee and Dr. Xue's family members as the beneficiaries, the "**Family Trust**"). Under the terms of the Family Trust, Dr. Xue has the power to exercise all the voting rights attached to the Shares. Accordingly, Dr. Xue is deemed interested in the Shares held by the Family Trust.
- (4) Dr. Xue beneficially holds 733,050 Shares under his own name and 106,091 Shares via a nominee which were derived from the exercising of share options.

By Order of the Board
CANbridge Pharmaceuticals Inc.
 北海康成製藥有限公司
Dr. James Qun Xue
 Chairman

Hong Kong, March 10, 2026

As of the date of this announcement, the Board comprises Dr. James Qun Xue as executive Director, Ms. Zhao Wei and Mr. Wang Tingwei as non-executive Directors, and Dr. Richard James Gregory, Mr. James Arthur Geraghty, Mr. Peng Kuan Chan and Dr. Lan Hu as independent non-executive Directors.